4.7 Article

Differential methylation of G-protein coupled receptor signaling genes in gastrointestinal neuroendocrine tumors

Journal

SCIENTIFIC REPORTS
Volume 11, Issue 1, Pages -

Publisher

NATURE RESEARCH
DOI: 10.1038/s41598-021-91934-5

Keywords

-

Funding

  1. National Cancer Institute at the National Institutes of Health [R21CA205796, P30CA042014]
  2. Huntsman Cancer Foundation
  3. National Cancer Institute's SEER Program [HHSN261201800016I]
  4. US Centers for Disease Control and Prevention's National Program of Cancer Registries [NU58DP006320]
  5. University of Utah
  6. NIH Shared Instrumentation Grant [1S10OD021644-01A1]

Ask authors/readers for more resources

This study identified significant methylation differences in NETs of the small intestine, with genes from the GPCR pathways being overrepresented in the differentially methylated genes. The results suggest that multiple GPCRs and their ligands are regulated through methylation and correlated with patient survival, providing opportunities for better treatment strategies for NETs based on molecular features.
Neuroendocrine tumors (NETs) of the small intestine undergo large chromosomal and methylation changes. The objective of this study was to identify methylation differences in NETs and consider how the differentially methylated genes may impact patient survival. Genome-wide methylation and chromosomal copy number variation (CNV) of NETs from the small intestine and appendix were measured. Tumors were divided into three molecular subtypes according to CNV results: chromosome 18 loss (18LOH), Multiple CNV, and No CNV. Comparison of 18LOH tumors with MultiCNV and NoCNV tumors identified 901 differentially methylated genes. Genes from the G-protein coupled receptor (GPCR) pathways are statistically overrepresented in the differentially methylated genes. One of the highlighted genes from the GPCR pathway is somatostatin (SST), a clinical target for NETs. Patient survival based on low versus high methylation in all samples identified four significant genes (p<0.05) OR2S2, SMILR, RNU6-653P, and AC010543.1. Within the 18LOH molecular subtype tumors, survival differences were identified in high versus low methylation of 24 genes. The most significant is TRHR (p<0.01), a GPCR with multiple FDA-approved drugs. By separating NETs into different molecular subtypes based on chromosomal changes, we find that multiple GPCRs and their ligands appear to be regulated through methylation and correlated with survival. These results suggest opportunities for better treatment strategies for NETs based on molecular features.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available